1. Home
  2. GITS vs TCRT Comparison

GITS vs TCRT Comparison

Compare GITS & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GITS

Global Interactive Technologies Inc.

HOLD

Current Price

$1.86

Market Cap

7.7M

Sector

N/A

ML Signal

HOLD

Logo Alaunos Therapeutics Inc.

TCRT

Alaunos Therapeutics Inc.

HOLD

Current Price

$1.99

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GITS
TCRT
Founded
2018
1998
Country
South Korea
United States
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.7M
6.7M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
GITS
TCRT
Price
$1.86
$1.99
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
144.5K
17.8K
Earning Date
05-19-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
24.66
EPS
N/A
N/A
Revenue
N/A
$15,900,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$1.67
52 Week High
$7.09
$5.48

Technical Indicators

Market Signals
Indicator
GITS
TCRT
Relative Strength Index (RSI) 51.42 29.64
Support Level $1.27 N/A
Resistance Level $2.71 $2.97
Average True Range (ATR) 0.34 0.23
MACD 0.02 -0.07
Stochastic Oscillator 45.19 3.42

Price Performance

Historical Comparison
GITS
TCRT

About GITS Global Interactive Technologies Inc.

Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.

About TCRT Alaunos Therapeutics Inc.

Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.

Share on Social Networks: